Don’t sell
michael e
Posts
-
-
Here she goes
-
No share left. 20 eod
-
Yuval Hadar law, one day all the shorts will be burned. That day is coming..
-
What append?
-
No. Its only 5% now and it means they was gaping only (arbitrage)
-
Not selling.
Buying the dip!! -
Vaxart: Stock Drop Following Phase 1 Data For Oral COVID-19 Vaccine Is A Buying Opportunity https://seekingalpha.com/article/4403369-vaxart-stock-drop-following-phase-1-data-for-oral-covidminus-19-vaccine-is-buying-opportunity
-
Not only that the lake of neutralising antibodies (specific to the corona virus) were not found on the participants who took a single doses only of the vaccine, but also have to be said that, however, they was found in nasal swab samples of the participants who received two doses...
What is the different between this vaccine and those of Pfizer and moderna??? They also need to use two doses...
However, our uniq advantages - no need for needles and the logistic one (room temperature) - still exist.How can someone say this results are disappointing?
We are attacked by tutes.
Keep your diamonds
-
In spite of absence of antibodies,Result are good !!
T-cell is the most important.
Dr tucker said next phase will start later on this Quarter!!
Holding long. Strong -
I told my group that "Understanding the risks of buying a company with only Phase 1 data that has not been fully evaluated by the scientific and medical communities, we could start new positions between $9 and $11."
Their data may not impress scientists right now, but I'm betting they will still get funding to proceed with the next phases. And the potential is intriguing for at least two reasons besides the possibility of a COVID pill.
First, if successful, they will be targeting a unique opportunity as the only "mucosal" vaccine after Merck recently abandoned their attempts. According to some doctors, novel coronavirus is a pathogen of a mucosal organ, different than those viruses that attack systemic organs. Current vaccines are systemic, and can only reduce disease severity.
Secondly, if successful, a pill for COVID could be room-temperature stable and not require extensive cold-chain technologies.
Why own more than one vaccine stock? Because the demand outstrips supply right now, plus countries want differentiated platforms and technology.
-
I told my group that "Understanding the risks of buying a company with only Phase 1 data that has not been fully evaluated by the scientific and medical communities, we could start new positions between $9 and $11."
Their data may not impress scientists right now, but I'm betting they will still get funding to proceed with the next phases. And the potential is intriguing for at least two reasons besides the possibility of a COVID pill.
First, if successful, they will be targeting a unique opportunity as the only "mucosal" vaccine after Merck recently abandoned their attempts. According to some doctors, novel coronavirus is a pathogen of a mucosal organ, different than those viruses that attack systemic organs. Current vaccines are systemic, and can only reduce disease severity.
Secondly, if successful, a pill for COVID could be room-temperature stable and not require extensive cold-chain technologies.
Why own more than one vaccine stock? Because the demand outstrips supply right now, plus countries want differentiated platforms and technology.
-
“Vaxart nonetheless be remains confident that its tablet will not only be able to treat the coronavirus but also handle the emerging new strains of the virus”
“Our Phase I results highlight the importance of our differentiated vaccine design, as they suggest VXA-CoV2-1 could have broad activity against existing and future coronavirus strains," Chief Executive Andrei Floroiu said in a statement.
-
Phase 1 was successful!
Phase 2 will start in Q1 (says Dr tucker on the webinar).
Can’t understand this oversell.
Holding long -
He said that Phase II will be made this Quarter !!!
-
Can someone put here a link to the conference?
-
Positive
Results -
- Wow. Told you
-
Yep
It’s green again
ANPC
ANPC
ANPC
ENLV
VXRT
BLRX
VXRT
VXRT
VXRT
VXRT
VXRT
VXRT
VXRT
VXRT
VXRT
VXRT
VXRT
VXRT
VXRT
VXRT